A New Generation of Therapy for Multiple Myeloma: The Clinical Role of Novel Treatment

Activity Description & Educational Objectives

In this activity, experts in the management of multiple myeloma discuss the rationale for pursuing next-generation therapy in the era of novel standards of care, with a focus on the need for such strategies in the salvage setting. In addition, the faculty review recent data on novel agents in pretreated myeloma and recommend settings for which clinical trial–based therapy that incorporates new agents can be considered.

Upon completion of this activity, participants should be better able to:

• Cite the clinical rationale for testing novel molecular pathways and targets in multiple myeloma
• Summarize safety and efficacy data on next-generation therapeutics in multiple myeloma
• Apply data on novel therapeutics active in myeloma to clinical practice, including as salvage therapy in relapsed/refractory patients and as clinical trial–based management

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other professionals engaged in the management of patients with multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: July 10, 2012 - July 09, 2013
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Interviewee

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Sagar Lonial, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Bristol-Myers Squibb; Celgene Corporation; Merck & Co. Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals, Inc.

Interviewee

Rafael Fonseca, MD
Professor of Medicine
Mayo Clinic
Scottsdale, Arizona

Rafael Fonseca, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Amgen Inc.; Bristol-Myers Squibb; Celgene Corporation; Eli Lilly and Company; Genzyme Corporation, a Sanofi company; Medtronic, Inc.; Millennium Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.; and Otsuka America Pharmaceutical, Inc.

Grant/Research Support from Cylene Pharmaceuticals and Onyx Pharmaceuticals, Inc.

Other Financial or Material Support from Fish probes for myeloma in the form of royalties, patents.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5135-12-T.

This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.